Contineum Therapeutics (CTNM) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Contineum Therapeutics (CTNM) has outperformed Rezolute (RZLT) over the past year, gaining 12.6% versus a loss of 41.1%. Contineum Therapeutics is the larger company by market cap ($503.4 million vs $471.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | RZLT |
|---|---|---|
| Share price | $13.38 | $4.87 |
| Market cap | $503.37M | $471.04M |
| 1-day change | +1.52% | +4.96% |
| YTD return | +17.06% | +106.36% |
| 1-year return | +12.63% | -41.11% |
| 5-year return | — | -26.77% |
| EPS (TTM) | $-1.73 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.79 | $11.46 |
| 52-week low | $8.60 | $1.07 |
| Distance from 52-week high | -24.77% | -57.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +67.64% | +101.23% |
| Average volume | 526.32K | 1.49M |
| Shares outstanding | 32.96M | 96.72M |
| Employees | 51 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTNM has outperformed RZLT by 53.7 percentage points over the past year.
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
CTNM vs RZLT FAQ
Which is bigger, Contineum Therapeutics or Rezolute?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $503.37M compared with $471.04M for Rezolute (RZLT).
Which stock has performed better over the past year, CTNM or RZLT?
CTNM returned +12.63% over the past 12 months, compared with -41.11% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Contineum Therapeutics and Rezolute in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.